KR20140135251A - 항종양 활성이 있는 신규 결합 분자 - Google Patents

항종양 활성이 있는 신규 결합 분자 Download PDF

Info

Publication number
KR20140135251A
KR20140135251A KR1020147029084A KR20147029084A KR20140135251A KR 20140135251 A KR20140135251 A KR 20140135251A KR 1020147029084 A KR1020147029084 A KR 1020147029084A KR 20147029084 A KR20147029084 A KR 20147029084A KR 20140135251 A KR20140135251 A KR 20140135251A
Authority
KR
South Korea
Prior art keywords
ser
gly
thr
leu
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147029084A
Other languages
English (en)
Korean (ko)
Inventor
사이먼 브락
프레데릭 무어란
이사벨라 토레르
리차드 우즈
율리안 베르트슁어
드라간 그라불로브스키
바베트 샤데
크리스티나 클룹쉬
헬렌 하헤미
Original Assignee
코바겐 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코바겐 아게 filed Critical 코바겐 아게
Publication of KR20140135251A publication Critical patent/KR20140135251A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147029084A 2012-03-16 2013-03-08 항종양 활성이 있는 신규 결합 분자 Ceased KR20140135251A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12159938.5 2012-03-16
EP12159938 2012-03-16
PCT/EP2013/054768 WO2013135588A1 (en) 2012-03-16 2013-03-08 Novel binding molecules with antitumoral activity

Publications (1)

Publication Number Publication Date
KR20140135251A true KR20140135251A (ko) 2014-11-25

Family

ID=47844323

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147029084A Ceased KR20140135251A (ko) 2012-03-16 2013-03-08 항종양 활성이 있는 신규 결합 분자

Country Status (12)

Country Link
US (2) US9593314B2 (enExample)
EP (1) EP2825197B1 (enExample)
JP (1) JP6325463B2 (enExample)
KR (1) KR20140135251A (enExample)
CN (1) CN104284675B (enExample)
AU (1) AU2013231488B2 (enExample)
BR (1) BR112014022932A2 (enExample)
CA (1) CA2865597A1 (enExample)
MX (1) MX354717B (enExample)
NZ (1) NZ629283A (enExample)
RU (1) RU2627185C1 (enExample)
WO (1) WO2013135588A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
MX376384B (es) 2013-11-27 2025-03-07 Zymeworks Bc Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
JP2017504325A (ja) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス,インコーポレイテッド バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションLycera Corporation レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
HUE055424T2 (hu) * 2014-03-17 2021-11-29 Mitsubishi Tanabe Pharma Corp Antitest-fynomer konjugátumok
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2954279C (en) 2014-07-07 2023-11-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
CA2968258A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
CN108697779B (zh) * 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
NZ750948A (en) 2016-11-21 2020-06-26 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
US10722589B2 (en) * 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
US20190153096A1 (en) 2017-10-02 2019-05-23 Covagen Ag Cd3/cd33 bispecific binding molecules
WO2019134981A1 (en) 2018-01-05 2019-07-11 Ac Immune Sa Misfolded tdp-43 binding molecules
AU2019220395B2 (en) 2018-02-14 2025-12-04 Abba Therapeutics Ag Anti-human PD-L2 antibodies
RU2018111298A (ru) * 2018-03-29 2019-10-01 Закрытое Акционерное Общество "Биокад" Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека
WO2020212593A1 (en) 2019-04-18 2020-10-22 Ac Immune Sa Novel molecules for therapy and diagnosis
CA3137882A1 (en) 2019-05-23 2020-11-26 Tamara SEREDENINA Anti-tdp-43 binding molecules and uses thereof
JP2022537337A (ja) 2019-06-18 2022-08-25 マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 金属錯体試薬を介するHisタグ付タンパク質などの標的分子への標識および/または担体の部位特異的、速度論的に不活性なコンジュゲーション
CA3161178A1 (en) 2019-11-20 2021-05-27 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Archaeal peptide recombinase - a novel peptide ligating enzyme
US20210188990A1 (en) 2019-12-11 2021-06-24 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
TW202221008A (zh) 2020-08-07 2022-06-01 瑞士商赫孚孟拉羅股份公司 製備蛋白質組成物之方法
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗tdp-43結合分子およびその使用
EP4204448A2 (en) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2 antibodies for macrophage and dendritic cell differentiation
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CR20240231A (es) 2021-11-16 2024-07-09 Ac Immune Sa Moléculas novedosas para terapias y diagnósticos
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CR20240378A (es) 2022-02-16 2024-10-03 Ac Immune Sa Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN120917043A (zh) 2023-03-08 2025-11-07 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025221736A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
AU2005287404B2 (en) * 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
BRPI0515589A (pt) 2004-09-02 2008-07-29 Genentech Inc polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
EP2464663A4 (en) * 2009-08-13 2013-05-29 Massachusetts Inst Technology MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS
CA2772162C (en) * 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック, インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
BR112012014194A2 (pt) * 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
CA3051311A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
WO2012009705A1 (en) * 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof

Also Published As

Publication number Publication date
CN104284675B (zh) 2017-07-18
EP2825197A1 (en) 2015-01-21
US9593314B2 (en) 2017-03-14
RU2627185C1 (ru) 2017-08-03
US20150047065A1 (en) 2015-02-12
CN104284675A (zh) 2015-01-14
WO2013135588A1 (en) 2013-09-19
MX354717B (es) 2018-03-16
US20170281768A1 (en) 2017-10-05
JP6325463B2 (ja) 2018-05-16
JP2015516801A (ja) 2015-06-18
AU2013231488B2 (en) 2017-12-07
AU2013231488A1 (en) 2014-09-18
NZ629283A (en) 2016-04-29
MX2014011066A (es) 2015-03-09
BR112014022932A2 (pt) 2017-07-18
CA2865597A1 (en) 2013-09-19
EP2825197B1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
JP6325463B2 (ja) 抗腫瘍活性を有する新規結合分子
US20240343824A1 (en) Binding molecules that inhibit cancer growth
US20210198380A1 (en) Anti-cancer fusion polypeptide
US11242405B2 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
JP6694808B2 (ja) 抗腫瘍活性を有する新規な二重特異的結合分子
EP3253795B1 (en) Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP7303391B2 (ja) バイアス型il2ムテイン、方法、および組成物
KR20190140943A (ko) 항-cd33 항체 제제
KR20180002780A (ko) 전립선 특이적 막 항원 결합 피브로넥틴 iii형 도메인
CN113045659B (zh) 抗cd73人源化抗体
KR20210075080A (ko) Her2-결합 사량체 폴리펩티드
EP2638916A1 (en) Novel binding molecules with antitumoral activity
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
KR20220131233A (ko) Semg2 항체 및 이의 용도
KR20130057959A (ko) 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
HK40062651A (en) Binding molecules that inhibit cancer growth
Miller Novel HER3 and IGF-1R Peptide Mimics and Synthetic Cancer Vaccines
HK1253914B (en) Binding molecules that inhibit cancer growth

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180308

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20180308

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180620

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180828

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180620

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I